INHBE and pulmonary arterial hypertension: In this review, we summarise the molecular mechanisms underpinning activin–BMP axis dysregulation in PAH, critically evaluate the clinical evidence for sotatercept across the disease spectrum and discuss its emerging role as a disease-modifying therapy within modern PAH management strategies.